UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant to~~PURSUANT ~~Section~~TO SECTION 13 orOR 15(d) of ~~the~~OF ~~Securities~~THE ~~Exchange~~SECURITIES ~~Act~~EXCHANGE ofACT OF 1934

Date of Report (Date of ~~Earliest~~earliest ~~Event~~event ~~Reported~~reported): ~~October~~ 2November 13, 2025

~~CYTOSORBENTS~~Cytosorbents ~~CORPORATION~~Corp

(Exact name of registrant as specified in its charter)

Delaware		001-36792		98-0373793
(State or other jurisdiction of incorporation)		(Commission File Number)		(~~I.R.S.~~IRS Employer Identification No.)

305 College Road East Princeton, New Jersey	08540
305 COLLEGE ROAD EAST PRINCETON, New Jersey		08540
(Address of principal executive offices)	~~(Zip Code)~~	(Zip code)

Registrant’'s telephone number, including area code: (~~732~~973) 329-8885

Not Applicable ~~(Former name or former address, if changed since last report.)~~

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value		NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities ~~registered~~Act ~~pursuant~~of to1933 ~~Section 12~~(b§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CTSO	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Emerging growth company ☐

~~Indicate~~If an emerging growth company, indicate by check mark ~~whether~~if the registrant ishas anelected ~~emerging~~not ~~growth~~to ~~company~~use asthe ~~defined~~extended intransition ~~Rule~~period ~~405~~for ofcomplying ~~the~~with ~~Securities~~any ~~Act~~new ofor ~~1933~~revised ~~(§230.405 of~~financial ~~this~~accounting ~~chapter)~~standards provided orpursuant ~~Rule~~to ~~12b-2~~Section 13(a) of the ~~Securities~~ Exchange Act ~~of 1934 (§240~~.~~12b-2~~ ~~of this chapter).~~☐

~~Emerging~~Item ~~Growth~~2.02. Results ~~Company~~of ¨Operations and Financial Condition.

IfOn anNovember ~~emerging~~13, ~~growth company~~2025, ~~indicate~~CytoSorbents byCorporation ~~check mark~~issued ifa ~~the~~press ~~registrant~~release ~~has~~announcing ~~elected~~its ~~not~~financial toresults ~~use~~for the ~~extended~~quarter ~~transition~~ended ~~period~~September 30, ~~for~~2025. ~~complying~~A ~~with~~copy ~~any~~of ~~new~~the orpress ~~revised~~release ~~financial~~is ~~accounting standards~~furnished ~~provided~~herewith ~~pursuant~~as toExhibit ~~Section 13(a) of the Exchange Act~~99. ¨1.*

Item 39.01 ~~Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.~~Exhibits

~~On October 2, 2025, CytoSorbents Corporation~~ (~~the “Company”~~d) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”).Exhibits

The written notification has no immediate effect on the listing or trading of the Company’s common stock. In accordance with applicable Nasdaq rules, the Company has 180 calendar days following the date of the written notice, or until March 31, 2026 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date, unless the Nasdaq staff exercises its discretion to require the Company to meet the Minimum Bid Price Requirement for a longer period pursuant to applicable Nasdaq rules.

Exhibit No.	Description
99.1	Press Release of the Company, dated November 13, 2025
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)

If* ~~the~~The ~~Company~~information ~~does~~in Item 2.02 of this Form 8-K shall not ~~regain~~be ~~compliance~~deemed ~~with~~“filed” ~~the~~for ~~Minimum~~purposes ~~Bid~~of ~~Price~~Section ~~Requirement~~18 byof the ~~Compliance~~Securities ~~Date~~Exchange Act of 1934, as amended (the ~~Company~~“Exchange ~~would~~Act”) beor ~~eligible for~~otherwise ansubject ~~additional~~to ~~compliance~~the ~~period~~liabilities of ~~180~~that ~~days~~section, ~~provided~~nor shall it ~~presents~~be andeemed ~~acceptable~~incorporated ~~plan~~by toreference ~~NASDAQ~~in toany ~~regain~~filing ~~compliance~~under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The Company intends to actively monitor the closing bid price of its common stock, and will consider its options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing standards.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 3, 2025	CYTOSORBENTS CORPORATION
Dated: November 13, 2025	CYTOSORBENTS CORPORATION
	By:	/s/ Dr. Phillip P. Chan
	Name:	Dr. Phillip P. Chan
	Title:	Chief Executive Officer

Filing Compare · Cytosorbents Corp